{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["10(12)"],"submitter":["Chen L"],"pubmed_abstract":["<h4>Background</h4>To explore the optimum induction therapy for patients with newly diagnosed multiple myeloma (NDMM) who are eligible but have not yet received autologous stem cell transplantation (ASCT) in China.<h4>Methods</h4>A total of 140 NDMM patients with cytogenetic background were selected from the Chang Zheng Hospital for this study. The induction therapy consisted of combined bortezomib (1.3 mg/m<sup>2</sup>, i.v.), cyclophosphamide (200 mg, i.v.), and dexamethasone (20 mg, i.v.) (VCD); or combined bortezomib (1.3 mg/m<sup>2</sup>, i.v.), epirubicin (50 mg/m<sup>2</sup>, i.v.), and dexamethasone (20 mg, i.v.) (PAD). All patients received 4-6 cycles of induction therapy until the first remission (defined as reaching at least partial remission), followed by thalidomide (100 mg/ev"],"journal":["Annals of translational medicine"],"pagination":["674"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9279781"],"repository":["biostudies-literature"],"pubmed_title":["Bortezomib, epirubicin, and dexamethasone (PAD) results in superior free-progression survival compared to bortezomib, cyclophosphamide, and dexamethasone (VCD) treatment in non-transplantation newly diagnosed multiple myeloma patients aged between 50 to 65: a retrospective single-center analysis in non-transplant patients."],"pmcid":["PMC9279781"],"pubmed_authors":["Yi K","Zhang Y","Jin S","Chen L","Fu W","Xian H","Mou X","Li R","Lan H"],"additional_accession":[]},"is_claimable":false,"name":"Bortezomib, epirubicin, and dexamethasone (PAD) results in superior free-progression survival compared to bortezomib, cyclophosphamide, and dexamethasone (VCD) treatment in non-transplantation newly diagnosed multiple myeloma patients aged between 50 to 65: a retrospective single-center analysis in non-transplant patients.","description":"<h4>Background</h4>To explore the optimum induction therapy for patients with newly diagnosed multiple myeloma (NDMM) who are eligible but have not yet received autologous stem cell transplantation (ASCT) in China.<h4>Methods</h4>A total of 140 NDMM patients with cytogenetic background were selected from the Chang Zheng Hospital for this study. The induction therapy consisted of combined bortezomib (1.3 mg/m<sup>2</sup>, i.v.), cyclophosphamide (200 mg, i.v.), and dexamethasone (20 mg, i.v.) (VCD); or combined bortezomib (1.3 mg/m<sup>2</sup>, i.v.), epirubicin (50 mg/m<sup>2</sup>, i.v.), and dexamethasone (20 mg, i.v.) (PAD). All patients received 4-6 cycles of induction therapy until the first remission (defined as reaching at least partial remission), followed by thalidomide (100 mg/ev","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Jun","modification":"2025-04-27T03:14:30.757Z","creation":"2025-04-06T18:49:37.453Z"},"accession":"S-EPMC9279781","cross_references":{"pubmed":["35845500"],"doi":["10.21037/atm-22-394"]}}